Page 84 - AN-4-2

Advanced Neurology Brain bioavailability of targeted protein degraders

141. Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, doi: 10.1126/science.170.3963.1212
Dowling TC. Evaluation of P-glycoprotein-mediated
renal drug interactions in an MDR1-MDCK model. 152. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier
permeation molecular parameters governing passive
Pharmacotherapy. 2003;23(4):436-442.
diffusion. J Membr Biol. 1998;165(3):201-211.
doi: 10.1592/phco.23.4.436.32125
doi: 10.1007/s002329900434
142. Evers R, Zaman GJ, van Deemter L, et al. Basolateral 153. Clark DE. Rapid calculation of polar molecular surface area
localization and export activity of the human multidrug and its application to the prediction of transport phenomena.
resistance-associated protein in polarized pig kidney cells. 2. Prediction of blood-brain barrier penetration. J Pharm
J Clin Invest. 1996;97(5):1211-1218.
Sci. 1999;88(8):815-821.
doi: 10.1172/JCI118535
doi: 10.1021/js980402t
143. Jeliazkova-Mecheva VV, Bobilya DJ. A porcine astrocyte/ 154. Kargbo RB. Treatment of Alzheimer’s by PROTAC-Tau
endothelial cell co-culture model of the blood-brain barrier. protein degradation. ACS Med Chem Lett. 2019;10(5):
Brain Res Brain Res Protoc. 2003;12:91-98. 699-700.
doi: 10.1016/j.brainresprot.2003.08.004 doi: 10.1021/acsmedchemlett.9b00083
144. Ledwig V, Reichl S. Isolation and cultivation of porcine 155. Gosselet F, Loiola RA, Roig A, Rosell A, Culot M. Central
endothelial cells, pericytes and astrocytes to develop an nervous system delivery of molecules across the blood-brain
in vitro blood-brain barrier model for drug permeation barrier. Neurochem Int. 2021;144:104952.
testing. Pharmaceutics. 2023;15:1688.
doi: 10.1016/j.neuint.2020.104952
doi: 10.3390/pharmaceutics15061688
156. Xiong B, Wang Y, Chen Y, et al. Strategies for structural
145. Békés M, Langley DR, Crews CM. PROTAC targeted protein modification of small molecules to improve blood-brain
degraders: The past is prologue. Nat Rev Drug Discov. barrier penetration: A recent perspective. J Med Chem.
2022;21(3):181-200. 2021;64(18):13152-13173.
doi: 10.1038/s41573-021-00371-6 doi: 10.1021/acs.jmedchem.1c00910
146. Mares A, Miah AH, Smith IED, et al. Extended 157. Hanig JP, Morrison JM Jr., Krop S. Ethanol enhancement
pharmacodynamic responses observed upon PROTAC- of blood-brain barrier permeability to catecholamines in
mediated degradation of RIPK2. Commun Biol. chicks. Eur J Pharmacol. 1972;18(1):79-82.
2020;3(1):140.
doi: 10.1016/0014-2999(72)90134-3
doi: 10.1038/s42003-020-0868-6
158. Broadwell RD, Salcman M, Kaplan RS. Morphologic effect
147. Haid RTU, Reichel A. Transforming the discovery of targeted of dimethyl sulfoxide on the blood-brain barrier. Science.
protein degraders: The translational power of predictive PK/ 1982;217(4555):164-166.
PD modeling. Clin Pharmacol Ther. 2024;116(3):770-781.
doi: 10.1126/science.7089551
doi: 10.1002/cpt.3273
159. Azmin MN, Stuart JF, Florence AT. The distribution and
148. David L, Wenlock M, Barton P, Ritzén A. Prediction of elimination of methotrexate in mouse blood and brain
chameleonic efficiency. ChemMedChem. 2021;16(17): after concurrent administration of polysorbate 80. Cancer
2669-2685. Chemother Pharmacol. 1985;14(3):238-242.
doi: 10.1002/cmdc.202100306 doi: 10.1007/BF00258124

149. Chen W, Jin D, Shi Y, Zhang Y, Zhou H, Li G. The underlying 160. Sakane T, Tanaka C, Yamamoto A, et al. The effect of
mechanisms of lorlatinib penetration across the blood‐brain polysorbate 80 on brain uptake and analgesic effect of
barrier and the distribution characteristics of lorlatinib in D-kyotorphin. Int J Pharm. 1989;57(1):77-83.
the brain. Cancer Med. 2020;9(12):4350-4359.
doi: 10.1016/0378-5173(89)90266-4
doi: 10.1002/cam4.3061
161. Chen J, Escoffre JM, Romito O, et al. Enhanced
150. Bernatz S, Ilina EI, Devraj K, et al. Impact of docetaxel on macromolecular substance extravasation through the blood-
blood-brain barrier function and formation of breast cancer brain barrier via acoustic bubble-cell interactions. Ultrason
brain metastases. J Exp Clin Cancer Res. 2019;38(1):434. Sonochem. 2024;103:106768.
doi: 10.1186/s13046-019-1427-1 doi: 10.1016/j.ultsonch.2024.106768
151. Lloyd K, Hornykiewicz O. Parkinson’s disease activity of 162. Veszelka S, Mészáros M, Porkoláb G, et al. Effects of
l-dopa decarboxylase in discrete brain regions. Science. hydroxypropyl-beta-cyclodextrin on cultured brain
1970;170(3963):1212-1213. endothelial cells. Molecules. 2022;27(22):7738.

Volume 4 Issue 2 (2025) 78 doi: 10.36922/an.5140